TY - JOUR
T1 - Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation
T2 - An International Collaboration
AU - Giannatempo, Patrizia
AU - Pond, Gregory R.
AU - Sonpavde, Guru
AU - Albany, Costantine
AU - Loriot, Yohann
AU - Sweeney, Christopher J.
AU - Salvioni, Roberto
AU - Colecchia, Maurizio
AU - Nicolai, Nicola
AU - Raggi, Daniele
AU - Rice, Kevin R.
AU - Flack, Chandra K.
AU - El Mouallem, Nemer R.
AU - Feldman, Hope
AU - Fizazi, Karim
AU - Einhorn, Lawrence H.
AU - Foster, Richard S.
AU - Necchi, Andrea
AU - Cary, Clint
PY - 2016
Y1 - 2016
N2 - Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p
AB - Purpose: We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods: Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results: Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4-63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p
KW - Cell transformation, neoplastic
KW - Drug therapy
KW - Neoplasms, germ cell and embryonal
KW - Teratoma
KW - Testicular neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84969534998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969534998&partnerID=8YFLogxK
U2 - 10.1016/j.juro.2015.12.082
DO - 10.1016/j.juro.2015.12.082
M3 - Article
AN - SCOPUS:84969534998
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
ER -